ArticleCureus2026
Effects of Contrast Medium and Vertebral Measurement Levels on Computed Tomography-Based Body Composition Parameters: Skeletal Muscle and Adipose Tissue Analysis.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical impact of computed tomography-measured skeletal muscle status at the third cervical vertebra on definitive radiotherapy outcomes for head and neck squamous cell carcinoma.Japanese journal of radiology · 2026Article
- High visceral-to-subcutaneous fat area ratio is an unfavorable prognostic indicator in patients with uterine sarcoma.Japanese journal of radiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to evaluate the effects of contrast medium administration and vertebral measurement level (L3 and L1) on computed tomography (CT)-derived body composition parameters and to establish conversion equations to enable the normalization and harmonization of these metrics across heterogeneous imaging protocols, which would aid in oncology prognostication or opportunistic screening.
methodsA total of 203 dynamic contrast-enhanced CT examinations, including unenhanced (phase 0) and early arterial, late arterial, portal, and equilibrium phases (phases 1-4, respectively), were retrospectively enrolled in the study. Skeletal muscle area (SMA) and mean skeletal muscle density (MSMD), subcutaneous adipose tissue area (SATA) and mean subcutaneous adipose tissue density (MSATD), and visceral adipose tissue area (VATA) and mean visceral adipose tissue density (MVATD) were measured at the L3 and L1 levels across five phases (phases 0-4). Measurement changes among phases and levels were assessed statistically.
resultsThe percentage changes in SMA, SATA, and VATA in phases 1/2/3/4 from phase 0 were as follows: L3 SMA, +1.1%/+2.1%/+2.8%/+3.5%; L1 SMA, +2.0%/+2.7%/+3.0%/+3.7%; L3 SATA, -0.4%/-1.9%/-2.9%/-4.7%; L1 SATA, -0.3%/-2.2%/-3.5%/-6.1%; L3 VATA, -7.5%/-17.8%/-20.0%/-22.2%; and L1 VATA, -8.5%/-20.1%/-22.6%/-23.7%. Differences in MSMD, MSATD, and MVATD in phases 1/2/3/4 compared with phase 0 were as follows (Hounsfield units): L3 MSMD, +2.1/+5.8/+7.8/+9.6; L1 MSMD, +2.9/+7.7/+9.1/+9.8; L3 MSATD, +1.2/+3.7/+4.8/+6.2; L1 MSATD, +1.2/+3.8/+4.7/+5.6; L3 MVATD, +1.5/+4.1/+5.2/+6.1; and L1 MVATD, +1.9/+4.9/+5.8/+6.3. Values between L3 and L1 showed a strong linear correlation (coefficient of determination, 0.950-0.999), suggesting interchangeability.
conclusionThe effects of contrast phase and measurement level on CT body composition parameters were comprehensively characterized. These findings provide robust conversion equations that enable normalization of data from cohorts with mixed imaging protocols, thereby strengthening the prognostic value of body composition analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.